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The co-stimulatory receptor CD40 is a member of the
tumor necrosis factor receptor (TNFR) superfamily and
plays an important role in the control and regulation of
immune activation, especially in crosstalk between T cells
and antigen presenting cells (APCs). The natural ligand for
CD40 (CD40L, CD154) is expressed on activated T cells
and provides a major component of T cell “help” for the
immune response. Agonistic CD40 antibodies can substi-
tute for the function of CD154 on T cells to boost immu-
nity by stimulating antigen presentation and co-stimulation
to T cells and have been shown to be potent boosters of
anti-tumor immune responses. Anti-CD40 can directly
inhibit tumor growth in CD40 expressing tumor cells.
APX005M is a humanized IgG1 monoclonal antibody
that binds CD40 with high affinity and blocks the binding
of CD40 to CD40L. APX005M activates dendritic cells,
B cells and monocytes, and promotes antigen-specific
T cell responses. APX005M demonstrates potent anti-
tumor activity via ADCC and induction of apoptosis in
CD40 expressing tumor cells. In comparison with other
CD40 agonistic antibodies such as CP-870, 893 and SGN-
40 analogs, APX005M has more potent CD40 agonistic
effects and antibody effector function.
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